-
Product Insights
NewSorrento Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Sorrento Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Sorrento Therapeutics Inc (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is also investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the...
-
Innovation Ranking
Innovation Ranking – Sorrento Therapeutics Inc
Sorrento Therapeutics Inc (Sorrento) is a biopharmaceutical company that focuses on developing therapeutics for the treatment of cancer, osteoarthritis and autoimmune diseases. The company’s immunotherapy pipeline portfolio consists of a CD38 CAR-T, CD38 ADC, CD38 DAR-T and Sephrehvir for the treatment of cancer. Sorrento is investigating COVID19 programs which include Coviguard, Covidrops and Covishield, among others for the treatment of COVID-19. Its marketed products include ZTlido, a lidocaine topical system for the treatment of postherpetic neuralgia (PHN). The company works...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PAC-1 in Pancreatic Endocrine Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PAC-1 in Pancreatic Endocrine Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PAC-1 in Pancreatic Endocrine Tumor Drug Details: PAC-1 (also known...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAV-AQP1 in Xerostomia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAV-AQP1 in Xerostomia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAV-AQP1 in Xerostomia Drug Details: AAV-AQP1 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabozantinib S-malate in Penile Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabozantinib S-malate in Penile Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabozantinib S-malate in Penile Cancer Drug Details: Cabozantinib s-malate (XL184,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxolitinib Phosphate in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxolitinib Phosphate in Hypopharyngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxolitinib Phosphate in Hypopharyngeal Cancer Drug Details: Ruxolitinib (INCB18424, Jakafi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Etrasimod in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Etrasimod in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Etrasimod in Atopic Dermatitis (Atopic Eczema) Drug Details: Etrasimod...
-
Company Insights
Innovation and Patenting activity of Sorrento Therapeutics Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Sorrento Therapeutics Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewClear Cell Squamous Cell Carcinoma – Drugs In Development, 2024
Empower your strategies with our Clear Cell Squamous Cell Carcinoma  – Drugs In Development, 2024 report and make more profitable business decisions. Clear cell squamous cell carcinoma (SCC), or hydropic SCC, is an extremely rare variant of SCC. It may be caused by ultraviolet radiation. It is usually not life-threatening, but if left untreated, it can grow large or spread to other parts of the body. Symptoms include a rough, reddish, scaly area; a dome-shaped or wart-like growth; a new...